Childhood Kidney Diseases

Korean Society of Pediatric Nephrology (대한소아신장학회)
권호 표지
DOI QR코드

DOI QR Code

Efficacy of Dextranomer/Hyaluronic Acid Copolymer ($Deflux^{(R)}$) Injection for Vesicoureteral Reflux in Children

방광요관역류 환아에서 내시경적 요관 점막하 Dextranomer/hyaluronic acid copolymer ($Deflux^{(R)}$) 주사요법의 효과에 대한 연구

  • Hong, Suk-Jin (Department of Pediatrics, Kyungpook National University School of Medicine) ;
  • Hwng, Hyun-Hee (Department of Pediatrics, Fatima Hospital) ;
  • Hong, Eun-Hui (Department of Pediatrics, Kyungpook National University School of Medicine) ;
  • Cho, Min-Hyun (Department of Pediatrics, Kyungpook National University School of Medicine) ;
  • Chung, Sung-Kwang (Department of Urology, Kyungpook National University School of Medicine)
  • 홍석진 (경북대학교 의학전문대학원 소아과학교실) ;
  • 황현희 (창원파티마병원 소아청소년과) ;
  • 홍은희 (경북대학교 의학전문대학원 소아과학교실) ;
  • 조민현 (경북대학교 의학전문대학원 소아과학교실) ;
  • 정성광 (경북대학교 의학전문대학원 비뇨기과학교실)
  • Published : 2009.10.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose : The aim of this study was evaluating the efficacy of endoscopic $Deflux^{(R)}$ submucosal injection in children with primary vesicoureteral reflux (VUR). Methods : Retrospective analysis of medical record was conducted on 38 children (59 ureters) who underwent endoscopic $Deflux^{(R)}$ injection due to primary VUR. Data were collected from March 2000 to February 2006. Mean infused amount of $Deflux^{(R)}$ was 0.77 cc. After $Deflux^{(R)}$ injection, patients were reassessed by voiding cystourethrogram (VCUG) 6 months later. Results : The success rate of endoscopic $Deflux^{(R)}$ submucosal injection 6 months later by VCUG was 100% for grade 1 VUR, 87.5% for grade 2, 60% for grade 3, 26.6% for grade 4, 16.6% for grade 5, respectively and there was negatively significant correlation between success rate and grade of VUR (P<.01). Degree of improvement of VUR by endoscopic $Deflux^{(R)}$ submucosal injection was not related to age at diagnosis, time to operation, existence of voiding dysfunction or constipation and infused amount of $Deflux^{(R)}$. However, group with anticholinergics medication had significantly lower success rate than non-medication group (P<0.047). Conclusion : Endoscopic $Deflux^{(R)}$ submucosal injection is effective therapy in patient with primary VUR, especially low grade VUR. It can be not only a useful substitute for prophylaxis with antibiotics, but also an effective management prior to ureteroneocystostomy in children with primary VUR.

목적 : 방광요관역류에 대한 치료법으로 최근 시행되고 있는 내시경적 요관 점막하 $Deflux^{(R)}$ (Dextranomer/hyaluronic acid copolymer) 주사요법의 효과에 대해 알아보고자 하였다. 방법 : 2000년 3월부터 2006년 2월까지 경북대병원 소아과에 내원하여 일차성 방광요관역류로 진단받고 이후 비뇨기과에서 내시경적 $Deflux^{(R)}$ 주사요법을 시행 받은 38명(59요관)을 대상으로 하였다. 의무기록을 통한 후향적 연구를 시행하였으며, 시술 6개월 후에 VCUG를 시행하여 방광요관역류의 치료 성공 및 호전 정도를 조사하였다. 결과 : 대상 환아의 평균연령은 2년 7개월이었으며 남녀비는 17:21이었다. 양측성이 21명(55.3%), 일측성이 17명(44.7%)이었으며 역류를 처음으로 진단받은 뒤 평균 24개월 후에 내시경적 $Deflux^{(R)}$ 주사요법을 시행 받았고 평균 주입량은 0.77 cc 였다. 시행 후 성공률은 Grade 1에서 100%, Grade 2에서 87.5%, Grade 3에서 60%, Grade 4에서 20%, Grade 5에서 16.6%였으며(r=-0.99, P=0.02), 호전률은 단계별로 각각 100%, 75%, 100%, 80%, 83% 이었다(r=-0.39, P=0.21). 즉, 방광요관역류의 단계와 호전률 사이에는 의미 있는 상관관계가 없었으나, 방광요관역류의 단계가 높을수록 성공률이 의미 있게 감소하였다. 그밖에, 방광요관역류의 진단 당시 연령, $Deflux^{(R)}$ 시술까지의 시간, $Deflux^{(R)}$ 주입량, 배뇨장애 유무, 변비의 유무와 성공률은 통계학적으로 의미 있는 상관관계를 보이지 않았고, 항콜린제 사용군에서 성공률이 의미 있게 낮았다. 결론 : 내시경적 요관 점막하 $Deflux^{(R)}$ 주사요법은 역류단계가 낮은 환아에서는 효과적인 치료법으로, 예방적 항생제 요법을 대신하고 개복 수술 전 단계로 시행할 만한 바람직한 방법으로 생각된다.

Keywords

References

  1. Capozza N, Caione P. Vesicoureteral reflux: surgical and endoscopic treatment. Pediatr Nephrol 2007;22:1261-5. https://doi.org/10.1007/s00467-006-0415-9
  2. Stenberg A, Lackgren G. A new bioimplant for the endoscopic treatment of vesicoureteral reflux: experimental and short-term clinical results. J Urol 1995;154:800-3. https://doi.org/10.1016/S0022-5347(01)67168-4
  3. Austin JC, Cooper CS. Vesicoureteral reflux: surgical approaches. Urol Clin North Am 2004;31:543-57. https://doi.org/10.1016/j.ucl.2004.04.018
  4. Grebeldinger S, Radojci B, Meljnikov I, Balj S. Treatment of vesicouretheral reflux in pediatric patients. Vojnosanit Pregl 2009;66:388-94. https://doi.org/10.2298/VSP0905388G
  5. Medical versus surgical treatment of primary vesicoureteral reflux: report of the International Reflux Study Committee. Pediatrics 1981;67:392-400.
  6. Giannotti P, Pistolesi D, Cuttano MG. Endoscopic treatment of vesico-renal reflux with teflon: personal experience among adults and neurologic patients. Arch Ital Ural Androl 1997;69 Suppl 1:47-53.
  7. Capozza N, Caione P. Dextranomer/hyaluronic acid copolymer implantation for vesico-ureteral reflux: a randomized comparison with antibiotic prophylaxis. J Pediatr 2002;140:230-4. https://doi.org/10.1067/mpd.2002.121380
  8. Calisti A, Oriolo L, Perrotta ML, Spagnol L, Rocca M, Fabbri R. Endoscopic subureteral injection for vesicoureteral reflux and the risk of overtreatment. Minerva Pediatr 2009;61:1-7.
  9. Caballero M, Bernal-Sprekelsen M, Calvo C, FarrX, QuintL, Als L. Polydimethylsiloxane versus polytetrafluoroethylene for vocal fold medialization: histologic evaluation in a rabbit model. J Biomed Mater Res B Appl Biomater 2003;67:666-74.
  10. Steyaert H, Sattonnet C, Bloch C, Jaubert F, Galle P, Valla JS. Migration of PTFE paste particles to the kidney after treatment for vesicoureteric reflux. BJU Int 2000;85:168-9. https://doi.org/10.1046/j.1464-410x.2000.00451.x
  11. Leonard MP, Canning DA, Peters CA, Gearhart JP, Jeffs RD. Endoscopic injection of glutaraldehyde cross-linked bovine dermal collagen for correction of vesicoureteral reflux. J Urol 1991;145:115-9.
  12. Al-Hunayan AA, Kehinde EO, Elsalam MA, Al-Mukhtar RS. Outcome of endoscopic treatment for vesicoureteral reflux in children using polydimethylsiloxane. J Urol 2002;168:2181-3. https://doi.org/10.1016/S0022-5347(05)64349-2
  13. Herz D, Hafez A, Bagli D, Capolicchio G, McLorie G, Khoury A. Efficacy of endoscopic subureteral polydimethylsiloxane injection for treatment of vesicoureteral reflux in children: a North American clinical report. J Urol 2001;166:1880-6. https://doi.org/10.1016/S0022-5347(05)65712-6
  14. Lackgren G, Wahlin N, Skoldenberg E, Stenberg A. Long-term follow-up of children treated with dextranomer/hyaluronic acid copolymer for vesicoureteral reflux. J Urol 2001;166:1887-92. https://doi.org/10.1016/S0022-5347(05)65713-8
  15. Lavelle MT, Conlin MJ, Skoog SJ. Subureteral injection of Deflux for correction of reflux: analysis of factors predicting success. Urology 2005;65:564-7. https://doi.org/10.1016/j.urology.2004.09.068
  16. Puri P, Mohanan N, Menezes M, Colhoun E. Endoscopic treatment of moderate and high grade vesicoureteral reflux in infants using dextranomer/hyaluronic acid. J Urol 2007;178:1714-6. https://doi.org/10.1016/j.juro.2007.03.172
  17. Stenberg, Larsson E, Lindholm A, Ronneus B, Stenberg A, Lackgren G. Injectable dextranomerbased implant: histopathology, volume changes and DNA analysis. Scand J Urol Nephrol 1999;33:355-61. https://doi.org/10.1080/003655999750016988
  18. Kirsch AJ, Perez-Brayfield MR, Scherz HC. Minimally invasive treatment of vesicoureteral reflux with endoscopic injection of dextranomer/hyaluronic acid copolymer: the Children's Hospitals of Atlanta experience. J Urol 2003;170:211-5. https://doi.org/10.1097/01.ju.0000072523.43060.a0
  19. Capozza N, Patricolo M, Lais A, Matarazzo E, Caione P. Endoscopic treatment of vesico-ureteral reflux: twelve years' experience. Urol Int 2001;67:228-31. https://doi.org/10.1159/000050993
  20. Altug U, Cakan M, Yilmaz S, Yalcinkaya F. Are there predictive factors for the outcome of endoscopic treatment of grade III-V vesicoureteral reflux with dextranomer/hyaluronic acid in children- Pediatr Surg Int 2007;23:585-9. https://doi.org/10.1007/s00383-007-1881-2